IgG4-Related Orbital Inflammation When Glucocorticoids Have Failed
Glucocorticoids are the standard first-line treatment for IgG4-related orbital inflammation, but a subset of patients do not achieve a sufficient response — or cannot sustain dose reduction without adverse effects. For these patients, a structured next-line protocol applies.
First-line failure condition
Glucocorticoid therapy is considered to have failed when the expected response is not met: inadequate reduction in orbital masses, persistent symptoms, or insufficient decrease in serum IgG4. Inability to taper the corticosteroid dose to a safe long-term level is an equally valid escalation trigger.
Next-line approach
Second-line management involves a monoclonal antibody directed at a B-cell surface target. The complete regimen — including patient selection criteria, dosing framework, and follow-up monitoring — is detailed in the full protocol.
References
DOI: 10.4103/tjo.tjo_12_17
- In patients refractory to glucocorticoids or unable to have their dose reduced sufficiently to avoid adverse effects of the long-term use, rituximab should be considered.
- Rituximab typically reserved as a second-line therapy because of high cost and potential side effects.
View source ↗